⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ACTU News
Actuate Therapeutics, Inc. Common stock
Form 8-K
sec.gov
ACTU
Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
globenewswire.com
ACTU
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com
ACTU
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
globenewswire.com
ACTU
Form 8-K
sec.gov
ACTU
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
globenewswire.com
ACTU
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
globenewswire.com
ACTU
Form 8-K
sec.gov
ACTU
Form 8-K
sec.gov
ACTU
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
globenewswire.com
ACTU